---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016796"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:23:12.185430+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva updates RECOVER OLE enrollment: 358 enrolled, 23 completed 12 months, NDA on track for Q4 2025

## Summary
- 358 patients enrolled; 223 currently on treatment across USA, Europe, and Asia.
- 23 patients have completed 12 months of treatment; targeting 100 for NDA submission.
- Brilaroxazine generally well tolerated in acute and stable schizophrenia patients.
- Topline 12-month safety data expected in Q4 2024; NDA submission planned for Q4 2025.

## SEC filing metadata
- accession: 0001437749-24-016796
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774924016796/0001437749-24-016796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774924016796/rvph20240514_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016796
- JSON: https://secwatch.observer/filing/0001437749-24-016796.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.